With the health and safety of members, volunteers, and attendees in mind, SNMMI made the decision to reschedule the SNMMI Therapeutics Conference, originally scheduled for November 11-13, 2021. The SNMMI Therapeutics Conference will now take place March 10-12, 2022, in New Orleans, LA. Read the full date change announcement.
SNMMI members can save 50% when they register to attend SNMMI's Online Nuclear Medicine Review Course and in-training resident members can register for free. This two-day course is the perfect resource to help you prepare for your board exam or use as a great general refresher to enhance your practice! Register.
ACNM Annual Meeting abstract submission window opens in September. Sign up to be contacted when more information becomes available for 2022 SNMMI Mid-Winter and ACNM Annual Meeting.
Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.
Appropriate Use Criteria (AUC) are statements that contain indications describing when, and how often, an intervention should be performed under the auspices of scientific evidence, clinical judgment, and patient values while avoiding unnecessary provisions of services. SNMMI follows a balanced multidisciplinary approach to guidance development by including various stakeholders in the development process. To view the development process, please click the following link: SNMMI AUC Development Process.
NEW AUCs:
Oncology |
Cardiology |
Neurology |
SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.
Guidelines
Appropriate Use Criteria
Dosimetry
Dose Optimization
NCCN's Guidelines Tabular Summary
NCCN Practice Guidelines Narrative Summary
The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:
SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.
Outreach Speaker Request Form
Outreach Program
FAQs
A novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer patients according to new research published in the May issue of JNM.
(Press Release)
The protein galectin-1 has been identified as a new PET imaging biomarker for immune checkpoint blockade therapy, allowing physicians to predict the tumor responses before beginning treatment, according to new research published in JNM.
(Press Release)
A new JNM supplement spotlights the role China has played in advancing global nuclear medicine, detailing significant advances in research and development as well as the clinical translation of novel radiopharmaceuticals.
(Press Release)
A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment, according to new research in JNM.
(Press Release)
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.